The latest report by IMARC, titled “Status Epilepticus Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2033”, finds that the global status epilepticus market size is witnessing steady growth. Status epilepticus (SE) refers to a medical emergency condition characterized by prolonged seizures that last for more than five minutes or recurrent seizures without regaining consciousness in between. It is a life-threatening condition that requires immediate medical attention as it can lead to permanent brain damage or even death. SE can occur in individuals with epilepsy, as well as those without a history of seizures. It can also be caused by various underlying medical conditions such as brain infections, head injuries, stroke, drug overdose, or withdrawal. Some of the common symptoms of this disease include continuous seizures, loss of consciousness, convulsions, difficulty breathing, and abnormal movements. Nowadays, several treatments are available for SE, including prompt administration of antiepileptic medications, as well as interventions to maintain the patient's airway, breathing, and circulation. In severe cases, hospitalization and intensive care may be necessary to monitor and manage the patient's condition.
Global Status Epilepticus Market Trends:
One of the primary factors driving the market is the rising incidence of epilepsy due to the occurrence of several risk factors, including neurological disorders, birth-related injuries, infections, and substance abuse. Additionally, the lack of access to appropriate medical care is another growth-inducing factor. Besides this, the increasing adoption of transcranial magnetic stimulation (TMS), a non-invasive therapy that involves the use of magnetic fields to stimulate the brain, is propelling the market growth. Apart from these factors, governments of various nations are taking initiatives to raise awareness about the disorder and assist in the development of better treatment options, which is creating a positive market outlook. Furthermore, the development of second- and third-generation anti-epileptic drugs with fewer side effects and drug interactions, as they are more potent and have a more favorable safety profile compared to traditional AEDs, is expected to drive the status epilepticus market during the forecast period. In line with this, significant technological advancements in electroencephalography (EEG) technology are easing the procedure of monitoring the patients with SE, thus catalyzing the market growth.
- Region-wise, the market has been classified into the United States, EU5 (Germany, France, the United Kingdom, Italy, and Spain), and Japan. The United States has the largest patient population for status epilepticus and represents the largest market for its treatment among the seven major markets.
- This research study?also offers a thorough overview of late-stage pipeline candidates and currently marketed medications for status epilepticus.
- The study also offers a thorough overview of the treatment practices for status epilepticus, the share of specific therapies, and?the performance of key market players.
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
134 N 4th St.
Brooklyn, NY 11249, USA
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800